AstraZeneca has announced the expansion of its existing drug discovery collaboration with X-Chem, which will support its long-term small molecule discovery strategy.
The revised agreement focuses on the synthesis and delivery of custom libraries to AstraZeneca, as well as the transfer of X-Chem's DEX platform. This will allow AstraZeneca to carry out in-house screening of DNA-encoded libraries.
“AstraZeneca and X-Chem have announced an expanded global drug discovery and technology transfer collaboration.“
This represents the third agreement between AstraZeneca and X-Chem since 2012, and builds on the success of existing collaborative work that has resulted in numerous licences to novel small molecules spanning multiple discovery programs and therapeutic indications.
X-Chem will receive upfront technology access and licence fees, and is eligible for additional payments linked to the exercise of specific technology transfer options and the achievement certain milestones.
Dr Menelas Pangalos, executive vice-president of AstraZeneca's innovative medicines and early development biotech unit, said: "This extended collaboration reflects the strength and success of our work with X-Chem over the past five years and secures long-term access to this capability."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical